A number of firms have modified their ratings and price targets on shares of Mirati Therapeutics (NASDAQ: MRTX) recently:

  • 10/12/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
  • 10/12/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $13.00 price target on the stock.
  • 10/5/2017 – Mirati Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. “
  • 10/2/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $13.00 price target on the stock.
  • 9/19/2017 – Mirati Therapeutics is now covered by analysts at Cann. They set an “outperform” rating on the stock.
  • 9/19/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $16.00 price target on the stock, up previously from $8.00.
  • 9/19/2017 – Mirati Therapeutics is now covered by analysts at CIBC. They set an “outperform” rating and a $18.00 price target on the stock.
  • 9/18/2017 – Mirati Therapeutics is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $18.00 price target on the stock.
  • 9/15/2017 – Mirati Therapeutics had its price target raised by analysts at Leerink Swann from $7.00 to $9.00. They now have a “market perform” rating on the stock.
  • 9/15/2017 – Mirati Therapeutics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 9/7/2017 – Mirati Therapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.

Mirati Therapeutics, Inc. (NASDAQ MRTX) opened at 15.75 on Monday. Mirati Therapeutics, Inc. has a 52 week low of $2.70 and a 52 week high of $16.50. The company’s market cap is $393.26 million. The company has a 50-day moving average of $10.79 and a 200 day moving average of $5.83.

In other Mirati Therapeutics news, SVP Jamie Christensen sold 4,000 shares of Mirati Therapeutics stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $14.00, for a total transaction of $56,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.10% of the company’s stock.

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Receive News & Ratings for Mirati Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.